National Research Institute, Wilshire

Los Angeles, California 90057

0 studies enrolling now · 18 studies all time

What they study most

Candidiasis, Vulvovaginal, Diabetes Mellitus, Type 2, Dyslipidemia, Dyslipidemias, High Cholesterol, Hypercholesterolemia, Hypertension, NAFLD, Non Alcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis, Obesity

Studies at this site

• A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight — Completed
• A Phase 2b Study of Icosabutate in Fatty Liver Disease — Completed
• Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) — Completed
• Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment — Stopped early
• Randomized Study of Obicetrapib as an Adjunct to Statin Therapy — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss — Completed
• A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program — Completed
• A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx — Completed
• A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics — Completed
• A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus — Completed
• Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) — Completed
• Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects — Completed
• A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease. — Completed
• Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) — Completed
• Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia — Stopped early
• The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects — Completed